



Sheet 1 of 3

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0286/ P0143-USw01	Application No. 10/506,388
		Applicant Stephen Martin Courtney, et al.	
		Filing Date April 14, 2005	Group Not Yet Assigned 1626
		Confirmation No. 1693	Examiner YONG CHU
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
YK	1	Bashkin, P., et al., "Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules," <i>Biochem.</i> , 1989, 28, 1737-1743	
	2	Database Chemcats Online, CAS, Database Accession No. 1575853, 2001, XP002240053, order number A0827/0038765, 1 page	
	3	Database Chemcats Online, CAS, Database Accession No. 604372, 2001, XP002240054, order number CHS 1040578, 1 page	
	4	Database Chemcats Online, CAS, Database Accession No. 126220, 2001, XP002240055, order number 2922-0873, 1 page	
	5	Demir, M., et al., "Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88)," <i>Clin. Appl. Thromb Hemost</i> , 2001, 7(2), 131-140	
	6	Fang, J., et al., "Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model," <i>Proc. Natl. Acad. Sci. USA</i> , 2000, 97(8), 3884-3889	
	7	Folkman, J., et al., "Control of angiogenesis by heparin and other sulfated polysaccharides," <i>Adv. Exp. Med. Biol.</i> , 1992, 313, 355-364	
	8	Kondragnati, S., et al., "Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion," <i>Cancer Res.</i> , 2000, 60, 6851-6855	
	9	Parish, C.R., et al., "Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel <i>in vitro</i> assays for angiogenesis," <i>Cancer Res.</i> , 1999, 59, 3433-3441	
YK	10	Parish, C.R., et al., "Treatment of central nervous system inflammation with inhibitors of basement membrane degradation," <i>Immunol. & Cell Biol.</i> , 1998, 76, 104-113	
EXAMINER		DATE CONSIDERED 1-15-2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0286/ P0143-USw01	Application No. 10/506,388
		Applicant Stephen Martin Courtney, et al.	
		Filing Date April 14, 2005	Group Not Yet Assigned 1626
		Confirmation No. 1693	Examiner YONG CHU
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
YK	11	Takuji, H., et al., "Thermoplastic polyester resin composition," <i>Patent Abstracts of Japan</i> 1989, esp@cenet database, 1 page	
YK	12	Tyle, P., "Iontophoretic devices for drug delivery," <i>Pharmaceutical Res.</i> , 1986, 3(6), 318-326	
YK	13	Vlodavsky, I., et al., "Inhibition of tumor metastasis by heparanase inhibiting species of heparin," <i>Invasion Metastasis</i> , 1994-95, 14, 290-302	
YK	14	Vlodavsky, I., et al., "Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis," <i>Nature Medicine</i> , 1999, 5(7), 793-802	
EXAMINER		Yong cl	DATE CONSIDERED 1-15-2006

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0286/ P0143-USw01	Application No. 10/506,388
	Applicant Stephen Martin Courtney, et al.	
	Filing Date April 14, 2005	Group <u>1626</u> Not Yet Assigned
	Confirmation No. 1693	<u>YONG CHU</u>

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
* <u>YC</u>	15	WO 01/35967 A1	05/25/01	PCT		<input checked="" type="checkbox"/>
<u>YC</u>	16	WO 02/060373 A3	08/08/02	PCT		
<u>YC</u>	17	01-247453	03/10/89	JP	X abstract	
<u>YC</u>	18	63-073425	04/04/88	JP	X abstract	
EXAMINER <u>Yong CH</u>				DATE CONSIDERED <u>01-11-2006</u>		

* 15 Not considered. Only abstract is in English, which is not enough to understand the patent. The rest is written in Germany. 2005 ww